Leaderboards/Gastrointestinal Tumor Research and Treatment

Gastrointestinal Tumor Research and Treatment

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Y.L. Verschoor
Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
2
Priscilla Merriam
Dana-Farber Cancer Institute
3
Harshil Dave
Indian Institute of Technology Gandhinagar
4
Ryugo Teranishi
Children's Hospital of Philadelphia
5
Xiongxin Lei
First People's Hospital of Foshan
6
Jinju Choi
Seoul National University Bundang Hospital
7
Alina Teuber
TU Dortmund University
8
Jirapat Wonglhow
Prince of Songkla University
9
Kennedy E. Okhawere
Icahn School of Medicine at Mount Sinai
10
Zhifeng Jiang
The Central Hospital of Xiao gan

Papers

1
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
Nature Medicine|2024
107 cit.
2
Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA
Nature Communications|2024
26 cit.
3
Publication in Bioactive Materials (2024) [25 citations, W4405774734]
Bioactive Materials|2024
25 cit.
4
Comparison of outcomes between single-port and multiport retroperitoneal robotic partial nephrectomy
Urologic Oncology Seminars and Original Investigations|2024
18 cit.
5
Publication in Journal of Robotic Surgery (2024) [6 citations, W4404414297]
Journal of Robotic Surgery|2024
6 cit.
6
Publication in Anticancer Research (2024) [2 citations, W4401022612]
Anticancer Research|2024
2 cit.
7
Publication in New England Journal of Medicine (2024) [1 citation, W4399370030]
New England Journal of Medicine|2024
1 cit.
8
Publication in Surgery Today (2024) [1 citation, W4400684763]
Surgery Today|2024
1 cit.
9
Publication in Journal of Urologic Oncology (2025) [1 citation, W4412764741]
Journal of Urologic Oncology|2025
1 cit.
10
Publication in The Journal of Urology (2024) [W4394801407]
The Journal of Urology|2024
0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Lenora A. Pluchino
National Comprehensive Cancer Network
2
Ina Felau
National Cancer Institute
3
Walid K. Chatila
Memorial Sloan Kettering Cancer Center
4
Karla Kopp
Mayo Clinic in Arizona
5
John A. Demchok
National Cancer Institute
6
Natália D. Aredes
Universidade Federal de Goiás
7
Michelle Bellair
Lunar and Planetary Institute
8
Moriah G. Nissan
Van Andel Institute
9
Li Jin
Third Affiliated Hospital of Zhengzhou University
10
Lisa A. Gurski
National Comprehensive Cancer Network

Papers

1
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network|2022
1.7k cit.
2
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network|2022
819 cit.
3
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network|2023
520 cit.
4
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
Journal of the National Comprehensive Cancer Network|2022
302 cit.
5
Bladder Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network|2024
236 cit.
6
NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network|2024
215 cit.
7
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
Journal of the National Comprehensive Cancer Network|2024
166 cit.
8
Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
Nature Medicine|2022
149 cit.
9
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022
Journal of the National Comprehensive Cancer Network|2022
76 cit.
10
Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers
Nature Communications|2023
51 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Jonathan A. Fletcher
Borders General Hospital
2
George D. Demetri
Dana-Farber Cancer Institute
3
Marc Ladanyi
Memorial Sloan Kettering Cancer Center
4
Jerzy Lasota
National Institutes of Health
5
Paolo G. Casali
Fondazione IRCCS Istituto Nazionale dei Tumori
6
Heikki Joensuu
Orion Corporation (Finland)
7
Murray F. Brennan
Memorial Sloan Kettering Cancer Center
8
Markku Miettinen
National Institutes of Health
9
Ronald P. DeMatteo
University of Pennsylvania
10
Jean‐Yves Blay
Université Claude Bernard Lyon 1

Papers

1
Comprehensive molecular characterization of gastric adenocarcinoma
Nature|2014
6.5k cit.
2
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
New England Journal of Medicine|2002
4.4k cit.
3
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
The Lancet|2006
2.6k cit.
4
Two Hundred Gastrointestinal Stromal Tumors
Annals of Surgery|2000
2.5k cit.
5
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Journal of Clinical Oncology|2003
2.3k cit.
6
<i>PDGFRA</i> Activating Mutations in Gastrointestinal Stromal Tumors
Science|2003
2.3k cit.
7
Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
New England Journal of Medicine|2001
2.1k cit.
8
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology|2018
1.6k cit.
9
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
New England Journal of Medicine|2006
1.4k cit.
10
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
The Lancet|2012
1.4k cit.

Reagents for Gastrointestinal Tumor Research and Treatment

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 66

Pbx1 Antibody

Cited in 7 papers
#4342$317
View Evidence →
Cell Signaling TechnologyEvidence 63

Streptavidin-HRP

Cited in 5 papers
#3999$176
View Evidence →
Cell Signaling TechnologyEvidence 67

beta-Amyloid (1-42) (D3E10) Rabbit Monoclonal Antibody

Cited in 5 papers
#12843$159,352
View Evidence →

🌟 All-Time

Most validated

Agilent/Dako

CD 117 (c-Kit, SCF-Receptor)

Cited in 37 papers
#A4502
View Evidence →
Cell Signaling TechnologyEvidence 66

LATS1 Antibody

Cited in 11 papers
#9153$317
View Evidence →
Cell Signaling Technology

SignalSlide® Phospho-Met (Tyr1234/1235) IHC Controls

Cited in 10 papers
#8118$196
View Evidence →